September 10, 2007, Lincoln, NE: LI-COR Biosciences announces successful completion of animal toxicity studies of its IRDye® 800CW infrared dye carboxylic acid using a protocol reviewed by the Food and Drug Administration. The completion of the toxicity studies is a key milestone in the development of the IRDye 800CW dye for potential clinical imaging use. LI-COR IRDye Infrared Fluorescent Dyes are used for protein and cellular assays, microscopy, and in vivo molecular imaging in animals for research purposes. IRDye 800CW is cited in a wide variety of published non-clinical research for labeling nucleic acids, antibodies, proteins, and peptides where there is a need for high signal, low background imaging. With an 800 nm emission wavelength, the IRDye 800CW dye is spectrally ideal for animal imaging research.
For more than 16 years scientists have used LI-COR infrared dyes for research including drug discovery, cell signaling analysis, animal imaging, and the Human Genome Project. LI-COR develops instrumentation, analysis software, and infrared reagents offering researchers a complete solution for protein analysis, genomics, and animal imaging.
"The unique characteristics of the IRDye 800CW Infrared Dye make it an excellent choice for molecular and small animal research," says Jeff Harford, LI-COR product manager. "Completing the animal toxicity studies is the logical next step in the development of the IRDye 800CW Infrared Dye for use in the clinical setting and is critical to our preparation for future clinical investigations."
While the IRDye 800CW Dye has successfully completed toxicity studies, it has not been studied for diagnostic or therapeutic use in humans, and has not been approved by the Food and Drug Administration for this use. LI-COR is exploring options for additional studies as next steps in the Food and Drug Administration approval process leading toward clinical use.
LI-COR Biosciences is a leader in the design and manufacture of instrument systems for biotechnology, plant biology and environmental research. LI-COR is a pioneer in the development of infrared fluorescence labeling and detection systems for such areas as drug discovery and DNA sequencing for genomic research. The Odyssey® and Aerius® systems offer unique infrared imaging solutions for protein analysis of Westerns, micro plate-based assays, and in vivo imaging.
Founded in 1971, the privately held company is based in Lincoln, Nebraska, with subsidiaries in Germany and the United Kingdom. LI-COR systems are used in more than 100 countries and are supported by a global network of distributors. Further information can be obtained at www.licor.com.